Real-Time Stability of Lyophilized Sabin Formulated Live Attenuated Bivalent Oral Polio Vaccine

Article Sidebar

PDF
Published: Apr 6, 2022
DOI: https://doi.org/10.47191/ijpbms/v2-i4-01
Keywords:
Sabin formulated bivalent Oral Polio Vaccine (sbOPV), Liquid sbOPV, lyophilized sbOPV, Stability, Room temperature, Physiochemical and Biological quality attributes

Main Article Content

Amit Kumar
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Oral Polio Vaccine Plant, Chola, Bulandshahr, Uttar Pradesh, Pin Code 203203, India
P.S.S. Sravan Kumar
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Oral Polio Vaccine Plant, Chola, Bulandshahr, Uttar Pradesh, Pin Code 203203, India
Surabhi Goyal
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Oral Polio Vaccine Plant, Chola, Bulandshahr, Uttar Pradesh, Pin Code 203203, India

Abstract

The stability of vaccines has a major impact on the success of immunization programmes worldwide. As part of its efforts to assure vaccine quality, ICH harmonized guideline for stability testing of new drug substances and product Q1A (R2) on 6th February 2003 has acknowledged the importance of clearly defining the stability characteristics of a vaccine and emphasizes the role of national regulatory authorities in overall vaccine evaluation. Therefore, this study was initiated with the aim of investigating the real-time stability of lyophilized Sabin formulated bivalent Oral Polio Vaccine (sbOPV) at room temperature. The stability of the lyophilized sbOPV was investigated through various quality attributes at room temperature for two consecutive years in our laboratory, such as physiochemical quality attributes (Colour, Appearance, Moisture content, pH and analysis of Magnesium Chloride) and biological including microbiological quality attributes (potency, identity, sterility, and kanamycin antibiotic activity). The results of the study revealed that lyophilized sbOPV is equally potent in comparison to currently used liquid sbOPV and also found stable at room temperature for two years, and also suggested that there is no need to maintain the cold chain system during transportation, and storage of lyophilized sbOPV.

Article Details

How to Cite
Amit Kumar, P.S.S. Sravan Kumar, & Surabhi Goyal. (2022). Real-Time Stability of Lyophilized Sabin Formulated Live Attenuated Bivalent Oral Polio Vaccine . International Journal of Pharmaceutical and Bio Medical Science, 2(4), 43–49. https://doi.org/10.47191/ijpbms/v2-i4-01
Issue
Vol. 2 No. 4 (2022): Volume 02 Issue 04 April 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Singh AK, Kumar A. Poliomyelitis: viruses and vaccines. As. Sud. Med. J., 2011; 6(7).

II. Kumar A, Tomar V. Review on Current Polio Vaccines: Vaccination schEdules and administration routes. Journal of Pharma Research, 2019; 8(4): 194-204.

III. Heleen K, Paul VH, Gideon K, Jean-Pierre A. Development of Thermostable Lyophilized Inactivated Polio Vaccine. Pharmaceutical Research, 2014; 31(10): 2618-2629.

IV. Shin W-J, Hara D, Gbormittah F, Chang H, Chang BS, Jung JU. Development of thermostable lyophilized Sabin inactivated poliovirus vaccine. mBio., 2018; 9(6): e02287-18.

V. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization. conclusions and recommendations. Wkly. Epidemiol. Rec., 2015; 90: 261-78.

VI. Kumar A, and Tomar V. Development of potent and stable lyophilize sabin formulated live attenuated bivalent oral polio vaccine. Eu.J.Bio.Pharma.Sci., 2019, Volume 6 (11), 218-226.

VII. Indian Pharmacopeia 7.0 edition, Volume I (978-93-81238-03-5,) (978-93-81238-07-3 set), Book No. 0480, Published by The Indian Pharmacopeia Commission Government of India, Ministry of Health and Family Welfare, India pharmacopeia laboratory Ghaziabad 2014.

VIII. International Conference Harmonization (ICH) Harmonized Tripartity Guidelines for Stability Testing of New Drug Substances and Products,

Q1A(R2) Current Step 4 version dated 6 February 2003.

IX. Shin W-J, Hara D, Gbormittah F, Chang H, Chang BS, Jung JU. Development of thermostable lyophilized Sabin inactivated poliovirus vaccine. mBio., 2018; 9(6): e02287-18.

X. Muller W, Firsching R. Studies on the presence of magnesium in visceral amyloid. Zentralbl Pathol., 1994: 140 (4-5):309-315.

XI. Jagannathan S, Mani KR, Vijayakumar R, Rahul Gandhi P and Venkataramana KN. Comparative analysis of Magnesium chloride in recently developed liquid state rabies vaccine. International Journal of Pharma and Bio Sciences, 2011; 2(3):473-479.

XII. Kumar A, Singh S P, Verma S, Kaushik R, Sharma N K. Quantitive evaluation of kanamycin in a single dose of oral polio vaccine in vitro. ISST Journal of Applied Chemistry, 2014; 5(1): 9-12.

XIII. Anh D D, Thiem V D, Hutagalung Y, Bock H L, Suryakiran P, Delem A, Han H H.. Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus Vaccine RIX4414 (RotarixTM) Oral Suspension (Liquid Formulation) in Vietnamese Infants. International Journal of Infectious Diseases, 2008; 12(1): 147.

XIV. World Health Organization (WHO). Forty-six WHO Experts Committee on specification for pharmaceutical preparation. International Pharmacopeia in 4th Edition 2012, Document QAS/11.413FINAL.

XV. Platt L R, Estívariz C F, Sutter R W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global